All In Biotech

Drug Trial Radar · NCT03648489

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Last checked: Nov 20, 2026Latest source record: Sep 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 134 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

134

Actual

Start

Sep 21, 2018

Primary completion

Nov 30, 2023

Study completion Nov 30, 2023

Sponsor

Lead sponsor
Imperial College LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Takeda Pharmaceuticals International, Inc.; North Eastern German Society of Gynaecological Oncology
First posted
Aug 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

DICE is a randomised study recruiting 126 women over 3 years from hospitals in the UK and Germany. Eligible patients will have tissue based diagnosis of advanced/recurrent ovarian cancer (clear cell, endometrioid or high grade serous or carcinosarcoma), have had chemotherapy before, and be platinum-resistant (the cancer has returned/grown significantly during or within 6 months of platinum-containing chemotherapy).

Conditions

  • Ovarian Cancer
  • Ovarian Neoplasms
  • Ovarian Carcinosarcoma
  • Ovarian Serous Adenocarcinoma
  • Ovarian Endometrioid Adenocarcinoma
  • Ovarian Clear Cell Adenocarcinoma
  • Fallopian Tube Cancer
  • Fallopian Tube Neoplasms
  • Primary Peritoneal Carcinoma
  • Primary Peritoneal Serous Adenocarcinoma

Interventions

  • PaclitaxelDrug

    Please refer to arm/group description

  • TAK228Drug

    Please refer to arm/group description

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: 12 months

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden, Germany

  • KEM Kliniken Essen-Mitte

    Essen, Germany

  • Churchill Hospital

    Oxford, United Kingdom

  • Weston Park Hospital

    Sheffield, United Kingdom

  • Southampton General Hospital

    Southampton, United Kingdom

  • Furness General Hospital

    Barrow in Furness, Cumbria, United Kingdom

  • St George's University Hospitals NHS Foundation Trust

    London, Greater London, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    London, Greater London, United Kingdom

  • Imperial College Healthcare NHS Trust

    London, Greater London, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    Sutton, Greater London, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, Greater Manchester, United Kingdom

  • Royal Lancaster Infirmary

    Lancaster, Lancashire, United Kingdom

  • Mount Vernon Cancer Centre

    Northwood, Middlesex, United Kingdom

  • Nottingham University Hospitals NHS Trust

    Nottingham, Nottinghamshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.